聚乙二醇脂质体多柔比星致肾脏局限性血栓性微血管病
本文报告2例聚乙二醇脂质体多柔比星(PLD)相关肾脏局限性血栓性微血管病(TMA),分别见于黏液纤维肉瘤和脂肪肉瘤患者。两例均接受高累积剂量PLD,表现为血肌酐升高和蛋白尿,肾活检示TMA伴慢性系膜溶解和毛细血管壁双轨征,停用PLD后血肌酐和蛋白尿改善或稳定。作者认为这2例提供了PLD与肾脏局限性TMA之间的明确因果联系。
要点
- 高累积剂量PLD可能增加肾脏TMA风险。
- PLD相关肾脏TMA表现为血肌酐升高和蛋白尿,肾活检示TMA伴慢性系膜溶解和毛细血管壁双轨征。
- 早期识别PLD相关肾脏TMA并及时停用PLD可能有助于保留肾功能。
核心结论
- 这2例病例提供了PLD与肾脏局限性TMA之间的明确因果联系。
- 高累积剂量PLD增加肾脏TMA风险。
- 早期识别PLD诱导的肾脏TMA可及时停用PLD并可能保留肾功能。
研究设计与样本
- 病例报告,共2例:1例黏液纤维肉瘤患者和1例脂肪肉瘤患者。
主要发现
- 2例患者均接受高累积剂量PLD,均出现血肌酐升高和蛋白尿。
- 肾活检显示TMA伴慢性系膜溶解和毛细血管壁双轨征。
- 2例均无吉西他滨、抗血管内皮生长因子药物或哺乳动物雷帕霉素靶蛋白抑制剂等TMA相关药物暴露。
- 2例继发性TMA病因检查均为阴性。
- 停用PLD后,2例患者的血肌酐和蛋白尿均改善或稳定。
临床怎么用
- 对接受高累积剂量PLD的患者,应关注血肌酐升高和蛋白尿,并考虑PLD相关肾脏局限性TMA的可能。
- 早期识别PLD相关肾脏TMA可及时停用PLD,可能有助于保留肾功能。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A definite causal link between pegylated liposomal doxorubicin (PLD) and kidney-limited thrombotic microangiopathy (TMA) remains unestablished. Here, we report 2 cases of PLD-induced kidney-limited TMA, 1 in a patient with myxofibrosarcoma and the other in a patient with liposarcoma. The 2 patients received a high cumulative dose of PLD, and both presented with a rise in serum creatinine and proteinuria. Kidney biopsy revealed TMA with chronic mesangiolysis and capillary wall double contouring. Neither patient had concomitant exposure to TMA-causing drugs, such as gemcitabine, anti-vascular endothelial growth factor agents, or mammalian target of rapamycin inhibitors. The work-up for secondary causes of TMA was negative in both patients. The cessation of PLD therapy led to improvement or stabilization in serum creatinine and proteinuria in both patients. These 2 cases provide a clear causal link between PLD and kidney-limited TMA. The high cumulative dose of PLD increases the risk of kidney TMA. Early recognition of PLD-induced kidney TMA can lead to timely cessation of PLD therapy and potentially preserve kidney function.
引用
- Glezerman I, Salvatore S, Tap W, et al. Pegylated Liposomal Doxorubicin Causes Kidney-limited Thrombotic Microangiopathy. Am J Kidney Dis. 2023. PMID: 37839689. doi:10.1053/j.ajkd.2023.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。